Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic : Canada announces commercial launch of Mazor™ X, the first dedicated robotic spinal surgery platform in Canada

10/25/2021 | 07:31am EST

BRAMPTON, ON, Oct. 25, 2021 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) – a global leader in healthcare technology, today announced the commercial launch of the Mazor™ X System (herein referred to as Mazor) for robotic-guided spine surgery. The Mazor platform offers a fully integrated procedural solution for surgical planning, workflow, execution and confirmation, and is the first dedicated robotic assisted spine surgery platform being launched in Canada.

The Mazor platform seamlessly incorporates existing StealthStation™ S8 surgical navigation capabilities into the Mazor Core Technology robotic-assisted surgery platform. Real-time image guidance, visualization and navigation are informed by interactive 3D planning and information systems to deliver workflow predictability and flexibility for procedures.

"The integration of navigation and robotic technologies into one platform is an exciting advancement in the field of spinal surgery," says Dr. Scott Paquette, orthopedic spine surgeon, and president of the Canadian Spine Society. "Mazor represents an incredible future of possibilities in spinal robotics, which I believe will greatly contribute to reduced risk for patients."

The three-dimensional Mazor platform allows surgeons to quickly visualize anatomy and spinal structures in relation to one another. This provides surgeons with access to plan and simulate spinal cages and screws in advance, with the goal of increasing efficiencies and surgical precision.

The best-in-class Midas Rex™ MR8 Electric High Speed Drill Systems are fully integrated throughout the Mazor system, enabling improved trajectory precision starting with pilot hole creation and offering attachments and dissecting tools designed to drill with accuracy at speeds up to 75,000 rpm. Surgeons can now use navigated interbody features on the Mazor system to visualize disc prep and interbody placement during a robotic procedure.

"Mazor embodies a synergy between robotics and navigation, providing a rigorous degree of accuracy integrated throughout the surgical procedure, with the hope of producing more reliable outcomes,"1 says Peter Tomashewski, senior director, Neuro and Spine Surgery, within the Cranial & Spinal Technologies business at Medtronic Canada. "The addition of Mazor to our portfolio provides another transformative tool that elevates our value driven solutions for spinal care."

Learn more at medtronic.ca/mazor

About Medtronic Canada ULC
Bold thinking. Bolder actions. We are Medtronic. Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC is headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, and is a subsidiary of Medtronic plc. We are the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic Canada, visit www.Medtronic.ca and follow @MedtronicCA on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1  Data on File.

SOURCE Medtronic Canada ULC

© Canada Newswire, source Canada Newswire English

All news about MEDTRONIC PLC
12/02MEDTRONIC PLC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
12/01Cloud DX selected by Medtronic for national collaboration
AQ
11/30Medtronic receives Health Canada licence for GI Genius™ intelligent endoscopy mod..
AQ
11/28Vincent Medical Strikes Product Distribution Deal with NYSE-listed Medtronic; Shares Ra..
MT
11/24JPMorgan Adjusts Medtronic's Price Target to $130 from $148, Keeps Overweight Rating
MT
11/24Bernstein Adjusts Medtronic's Price Target to $143 from $148, Keeps Outperform Rating
MT
11/24Stifel Adjusts Medtronic's Price Target to $140 from $145, Keeps Buy Rating
MT
11/24Raymond James Adjusts Medtronic's Price Target to $127 from $142, Keeps Outperform Rati..
MT
11/24Truist Securities Adjusts Medtronic's Price Target to $142 from $148, Keeps Buy Rating
MT
11/24Wells Fargo Adjusts Medtronic's Price Target to $137 From $144, Reiterates Overweight R..
MT
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 396 M - -
Net income 2022 5 378 M - -
Net Debt 2022 22 296 M - -
P/E ratio 2022 27,5x
Yield 2022 2,34%
Capitalization 144 B 144 B -
EV / Sales 2022 5,14x
EV / Sales 2023 4,75x
Nbr of Employees 90 000
Free-Float 99,8%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 107,28 $
Average target price 141,32 $
Spread / Average Target 31,7%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-9.96%144 277
ABBOTT LABORATORIES17.25%227 013
BECTON, DICKINSON AND COMPANY-3.42%68 717
HOYA CORPORATION24.39%57 923
DEXCOM, INC.51.53%54 298
SARTORIUS STEDIM BIOTECH65.52%50 244